Background. There is a paucity of patient-reported outcomes (PROs) data for people undergoing hepatitis C virus (HCV) treatment who are treated with opioid substitution therapy (OST) for addiction.
lower treatment uptake [19, 20] . Furthermore, particular medications such as interferon (IFN) can have significant neuropsychiatric side effects, which can further impair those patients' quality of life and, thus, negatively impact their adherence to treatment [20] .
Opioid substitution treatment (OST) provides both an effective treatment option for patients' addiction and a stable environment for patients to access healthcare, including anti-HCV treatment [21] . Although current or recent history of drug abuse is often an exclusion criterion for participating in clinical trials, recent studies allow enrollment of former PWIDs who are receiving OST. The impact of different anti-HCV regimens on PROs among both current PWIDs (ie, individuals currently injecting drugs) and former PWIDs receiving OST has not been previously studied. While similar PRO data for current PWIDs are not available at present, we assessed PROs of subjects with chronic HCV infection receiving OST who were undergoing treatment with different antiviral regimens in recent clinical trials of direct-acting antivirals (DAAs).
METHODS
The PRO data used in this study were collected in 21 multinational, multicenter, phase 3 clinical trials of various sofosbuvir (SOF)-containing regimens [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] in which SOF was used in combination with pegylated IFN and/or ribavirin (RBV) or with ledipasvir (LDV) or velpatasvir (VEL) with or without voxilaprevir (VOX). Participants of the trials were treatment naive or had previously not responded to anti-HCV treatment with an IFN-based or DAA-based regimen, were infected with any HCV genotype, did or did not have compensated or decompensated cirrhosis, were or were not coinfected with human immunodeficiency virus (HIV), were not coinfected with HBV, did not abuse alcohol or drugs within 12 months of screening (a positive result of a drug screen excluded subjects unless explained by a prescribed medication and approved by the investigator), and did not have any other major comorbidity as determined by the trials' investigators. The trials were conducted in 2013-2017 in the United States, Puerto Rico, Canada, Australia, New Zealand, Europe, and China.
Self-reported histories of depression, clinically overt fatigue, anxiety, sleep disorders, type 2 diabetes or hyperglycemia were collected at screening. Patients were considered to have achieved SVR for 12 consecutive weeks after treatment cessation (SVR-12) if they had undetectable HCV RNA at posttreatment week 12. Treatmentrelated adverse events were labeled as such by the investigators and were grouped by the body system or organ class. Adherence to treatment was defined as the percentage of prescribed pills and IFN doses taken by a patient, calculated as follows: [(total number of pills and doses dispensed) -(number of doses not taken and pills returned)]/[total number of pills and doses dispensed]; for multidrug regimens, the minimum value was selected.
In addition, subjects were considered to be receiving OST if they reported concomitant use of any drug from the World Health Organization Anatomical Therapeutic Chemical level 4 category termed "drugs used in opioid dependence, " which includes buprenorphine, buprenorphine hydrochloride, buprenorphine with naloxone, diamorphine, levomethadone, levomethadone hydrochloride, methadone, methadone hydrochloride, and Temgesic-nX.
Assessment of PROs and Health Utilities
The 4 PRO instruments used in this study-Short Form, Version 2 (SF-36v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV), and Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP)-have been widely used and extensively validated in patients with chronic diseases in both observational studies and clinical trials [38] [39] [40] [41] [42] [43] . In the clinical trials included in this study, those instruments were administered at baseline, at the last day of treatment, and in follow-up (weeks 4, 12, and 24 after treatment) to the study participants in their native languages. At each time point, patients were blinded to their most recent HCV RNA level prior to the questionnaire completion.
The SF-36v2 generic instrument assesses health-related quality of life (HRQL) by 8 individual domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The summary scores-physical component summary and mental component summary-summarize the physical and mental-health-related aspects of HRQL. These summary scores are calculated from the individual domains and are normalized to a general population mean (±SD) of 50 ± 10 [38] .
The FACIT-F is a fatigue-specific PRO instrument targeted to patients with a chronic illness [39] . It assesses 5 individual HRQL domains: physical, emotional, social, and functional well-being and a fatigue scale. The total FACIT-F score is the sum of the scores for the 5 domains.
The CLDQ-HCV is a disease-specific PRO instrument that is designed to assess HRQL in patients with chronic HCV infection via addressing the most frequently seen symptoms and manifestations of the disease, such as depression, fatigue, cognitive impairment, and insomnia [40, 41] . It includes 4 individual HRQL domains-activity and energy, emotional, worry, and systemicand the total score is an average of the scores for the 4 domains.
In addition to HRQL instruments described above, the WPAI:SHP instrument assesses impairment in work productivity and daily activities associated with a specific health problem (HCV infection) [42] . This instrument yields a work productivity impairment score (only in patients who report being employed), which is a sum of absenteeism (ie, lost productivity due to missed work hours) and presenteeism (ie, self-reported impairment in productivity while working) scores, and an activity impairment score (ie, impairment in activities other than work, measured regardless of employment). Unlike other instruments, the scores returned by the WPAI:SHP instrument are inversely related to health status, because a greater score represents more impairment in work productivity or activity.
We also calculated Short-Form Six-Dimension (SF-6D) scores by use of the SF-36v2 instrument to assess health utilities, which could further be used in cost-effectiveness analyses for calculation of quality-adjusted outcomes (most frequently, quality-adjusted life years). A nonparametric Bayesian algorithm was used as previously described [43] .
Statistical Analysis
Treatment regimens were classified as IFN+RBV-containing (SOF+IFN+RBV), IFN-free RBV-containing (SOF+RBV or LDV/SOF+RBV or SOF/VEL+RBV), and IFN-free RBV-free (LDV/SOF, SOF/VEL, SOF/VEL/VOX) regimens, regardless of treatment duration. The PROs and health utilities of patients receiving OST were summarized and compared to the scores of non-OST recipients in each treatment category separately; the nonparametric Mann-Whitney test was used for analysis. The decrements or improvements in PROs and utilities from patients' own baseline levels were calculated and compared to 0, using the signed rank test, and between patients receiving and those not receiving OST, using the rank sum test; all entries with nonmissing data were used.
Potential predictors of PROs and utilities in patients with HCV were evaluated in a series of generalized linear regression models. The treatment regimen and treatment duration, as well as age, sex, race/ethnicity, BMI, location, HIV coinfection, history of psychiatric disorders, history of type 2 diabetes, cirrhosis, and history of prior anti-HCV treatment, were tested as potential predictors of baseline PROs and of treatment-emergent PRO changes in all patients (with OST use being included as one of the PRO predictors) and in OST recipients separately. Bidirectional stepwise selection of predictors with a significance level of 0.05 for stay was used; thus, only factors with a P value of < .05 were considered independent predictors and left in the final regression models. All analyses were run in SAS 9.4 (SAS Institute, Cary, NC).
The study was approved by each site's institutional review board.
RESULTS
We analyzed 8450 patients with available concomitant medications data enrolled from 21 trials. Of those, 546 received IFN+SOF+RBV, 2919 received IFN-free RBV-containing regimens with SOF, with LDV/SOF, or with SOF/VEL, and 4570 received IFN-free RBV-free regimens (LDV/SOF, SOF/VEL, or SOF/VEL/VOX). There were 407 patients (4.8%) receiving OST at the time of participation in the trials, including 17 receiving IFN+RBV+SOF, 154 receiving IFN-free RBV-containing treatment, and 226 receiving IFN-free RBV-free treatment. Patients receiving OST had a mean age (±SD) of 49.0 ± 9.9 years, 72% were male, 90% were white, 33% were employed, 72% were treatment naive, 33% were cirrhotic, 11% were diabetic, and 17% were coinfected with HIV (Table 1) . In comparison to non-OST recipients, patients receiving OST were younger, with higher proportions being male, white, treatment-naive, cirrhotic, and coinfected with HIV, and had higher rates of pretreatment psychiatric comorbidities and insomnia (Supplementary Table 1) .
During treatment, patients receiving OST and treatment with IFN+RBV+SOF experienced the highest rates of treatment-related adverse events, followed by patients treated with IFN-free RBV-containing regimens (all P < .02; Table 1 ). In comparison to non-OST recipients, the rates of adverse events in patients receiving OST were not different during treatment with IFN+RBV+SOF (all P > .05), while treatment with IFN-free RBVcontaining regimens resulted in a higher rate of treatment-related anemia in patients receiving OST (16.2% vs 8.9%; P = .0023). The rates of SVR-12 were not different between patients receiving OST and those not receiving OST, regardless of the regimen used (100% and 87.0%, respectively, in the IFN+RBV+SOF group; 86% and 85%, respectively, in the IFN-free RBV-containing group; and 95.6% and 96.3%, respectively, in the IFN-free RBV-free group; all P > .10). The average adherence to treatment among patients receiving OST varied greatly between the hepatitis C treatment groups (P < .0001; Table 1 ) and was lower in comparison to adherence among non-OST recipients in all 3 regimen groups: 79.1% versus 89.1% in the IFN+RBV+SOF group, 86.7% versus 91.3% in the IFN-free RBV-containing group, and 94.5% versus 97.2% in the IFN-free RBV-free group (all P ≤ .05). At baseline, HCV-infected patients receiving OST had significantly lower PRO scores when compared to the non-OST group (all P < .0001; Supplementary Table 1) ; the impairment ranged from 3.5% to 15.6% of a PRO range size. Treatment-emergent changes in PROs varied between the treatment regimens used (Figure 1 and Supplementary Figure 1 ).
During treatment with IFN+RBV+SOF, patients receiving OST had decrements in their PROs of up to −18.8% of a PRO range size (P < .05 for 5 of 26 PRO domains); those decrements were all similar to those experienced by patients who were not receiving OST during treatment (all P > .05; Figure 2A and Supplementary Figure 2A) . Less profound decrements in PROs were experienced by patients treated with IFN-free RBV-containing regimens (up to −21.9% in work productivity and up to −5.0% in other PROs; P < .05 for 6 of 26 PRO domains), with findings again similar between OST recipients and non-OST recipients (P > .05 for all but 1 domain; Figure 2B and Supplementary Figure 2B ). In contrast, OST recipients treated with IFN-free RBV-free regimens experienced significant improvement (by 2.7%-12.6%; P < .05 for 17 of 26 PRO domains) in their PROs as early as 4 weeks into treatment, and some of those improvements were greater (by 2.2%-4.5%; P < .05 for 10 of 26 PRO domains) in comparison to those seen in non-OST recipients. Those improvements were also observed at the end of treatment, regardless of duration (from 3.0% to 15.2%; P < .05 for all but 2 PROs as compared to OST recipients' own baseline levels and for 11 of 26 PROs as compared to the same PRO improvements in non-OST recipients; Figure 2C and Supplementary Figure 2C) .
After treatment cessation, the treatment-emergent PRO impairment in patients treated with IFN+RBV+SOF was partly sustained through posttreatment week 4 ( Figure 1 ) but then resolved later during follow-up in both OST and non-OST recipients. However, residual impairment in some PRO scores was observed in OST recipients as late as 12 and 24 weeks after treatment, accompanied by a significant improvement in only 2 PRO scores, which were the emotional and worry domains of the CLDQ-HCV instrument ( Figure 3A and Supplementary Figure 3A) . At the same time, PRO improvements in non-OST recipients after successful treatment with IFN+RBV+SOF were significant starting at posttreatment week 12 and continued to increase throughout the follow-up period ( Figure 3A and Supplementary Figure 3A) . Abbreviations: ALT, alanine aminotransferase; HIV, human immunodeficiency virus; IFN-free RBV-free, therapy free of both pegylated interferon and ribavirin; IFN-free RBV+, therapy free of pegylated interferon but containing ribavirin; IFN+RBV+, therapy containing both pegylated interferon and ribavirin; SVR-12, sustained virologic response for 12 consecutive weeks after treatment cessation; ULN, upper limit of normal.
a Body mass index (BMI) is calculated as the weight in kilograms divided by the height in meters squared.
In OST recipients who completed IFN-free RBV-containing regimens, all PRO decrements completely resolved by posttreatment week 4 (increase from baseline, 3.6%-12.3% in 10 of 26 PRO domains), and improvements in PROs similar to those seen in non-OST recipients were observed throughout the follow-up period (increase from baseline, 4.2%-13.4% in 15 of 26 domains by posttreatment weeks 12 and 24; Figure 3B and Supplementary Figure 3B) .
Finally, in OST recipients who achieved SVR-12 after an IFNfree RBV-free regimen, all PRO improvements seen at the end of treatment were sustained or increased during posttreatment follow-up; those improvements were again similar or greater in comparison to those for non-OST recipients ( Figure 3C and Supplementary Figure 3C) .
Compared with IFN-and RBV-containing regimens, IFNfree RBV-free regimens were superior for OST recipients both during treatment and during the posttreatment follow-up period, with a P value of < . Figure 1A-C) .
In multivariate analysis, receiving OST was independently associated with lower PROs even after adjustment for higher rates of comorbidities (Table 2 ). In patients receiving OST, independent predictors of baseline PROs were similar to those previously reported for other HCV populations [44] [45] [46] [47] [48] and included age, sex, BMI, history of type 2 diabetes, cirrhosis, coinfection with HIV, clinically overt fatigue, and psychiatric comorbidities (Supplementary Table 2 ). Receiving IFN+RBV+SOF was highly predictive of lower PRO scores in patients receiving OST, after adjustment for the baseline levels and other PRO predictors ( Table 3 ). The association of IFN-free RBV-containing regimens with during-treatment PROs in patients receiving OST was also significant, but the magnitude of such association (ie, β) was substantially (1.7-2.9 times) smaller (Table 3) . By posttreatment week 12, the association of treatment regimen with the summary PROs remained significant for IFN+RBV+SOF recipients only, while similar associations in recipients of the IFN-free RBV-containing regimen, consistent with the observations made using univariate analysis, were no longer significant (all P > .05; Table 3 ).
DISCUSSION
To the best of our knowledge, this is the largest analysis of HCVinfected subjects receiving OST who were treated with different antiviral regimens. The study provided a number of important findings that may have clinical and public health implications. First, the data confirm that patients with HCV infection who are receiving OST can be treated with DAA-based regimens and achieve high rates of SVR that are comparable to those seen in other HCV-infected patients. Second, there is a clear indication that HCV-infected patients receiving OST experience a significant impairment in their PROs prior to the initiation of antiviral treatment. In fact, PRO scores for these patients further worsened during treatment with IFN-containing regimens and did not improve even after treatment cessation, while all other patients experienced improved scores during follow-up. The IFN+RBV-containing regimen also resulted in the lowest rate of adherence to treatment among HCV-infected subjects receiving OST. This indicates that IFN-based regimens may be not appropriate for treatment of HCV-infected patients receiving OST. Although the use of IFN-free RBV-containing regimens caused some impairment in PROs among patients receiving OST during treatment, that impairment was relatively mild, was reversible within weeks after treatment had been completed, and was soon followed by a significant improvement in PROs that was similar to that seen in non-OST recipients. This is important because, unlike IFN-containing regimens, which are rapidly becoming obsolete, RBV-containing regimens continue to be listed in guidelines as alternative treatment options for some subgroups of HCV-infected subjects. On the other hand, there was significant work productivity impairment associated with the use of RBV in OST recipients; this may have economic implications and should be further studied.
Present data clearly support the use of IFN-free RBV-free regimens for HCV-infected patients receiving OST in terms of high SVR rates and substantially better PRO scores during treatment and the posttreatment follow-up period. In fact, by the end of treatment with IFN-free RBV-free regimens, OST recipients experienced improvement of their PROs in nearly all (24 of 26) domains; for 18 of 26 domains, the average score improvement also exceeded the conservative estimate of the minimal clinically important difference, which is 5% of a PRO range size [49] . Furthermore, IFN-free RBV-free regimens had the highest adherence rates. However, despite slightly lower adherence rates as compared to subjects not receiving OST, SVR rates after completion of IFN-free RBV-free regimens were similar in both groups. Multivariate analysis showed that, in OST recipients, the use of IFN was a major independent predictor of PRO impairment both during treatment and after achieving SVR. Subjects who achieved SVR after IFN-free treatment experienced substantially improved PROs as compared to their baseline scores. This is important because improvement of PROs with SVR can be one of the most valuable outcomes to patients.
The main limitation of this analysis was the bias in the population and outcomes caused by strict enrollment criteria of the clinical trials and close monitoring of all patients throughout treatment duration. Given that, the generalizability of the findings must be additionally verified in pragmatic clinical trials. It is also important to emphasize that patients enrolled in this study were not current PWIDs, so it is unlikely that our findings can be directly applied to that population. Nevertheless, large sample size, availability of systematically collected clinical data, and use of a number of validated PRO instruments have provided a unique opportunity to assess treatment-emergent PROs in this clinically important population.
In summary, PROs are impaired in HCV-infected subjects who are receiving OST. While IFN-containing regimens further impair their PROs, the use of IFN-free regimens is associated with excellent efficacy, good-to-excellent tolerability, and improvement of PRO scores after achieving SVR. Furthermore, both SVR rates and PRO improvements in OST recipients treated with IFN-free regimens are noninferior or superior to those seen in the rest of HCV population. Given that, we propose that the use of IFN in this vulnerable HCV population may be not appropriate. Rather, it is IFN-free RBV-free DAA-based treatment that provides substantial advantages for patients receiving OST, including the highest rates of treatment adherence and SVR and the best patient experience during treatment.
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